CLT CLT Inflammation & Chronic Disease Connections 1 — Questions and Answers
Question 1: In the context of LEAP therapy, what is the primary mechanism by which food-induced inflammation contributes to chronic symptoms?
- Immediate IgE-mediated hypersensitivity
- Delayed mediator release from immune cells triggered by reactive foods (Correct answer)
- Structural damage to the intestinal villi
- Overproduction of stomach acid
Correct answer: Delayed mediator release from immune cells triggered by reactive foods
LEAP therapy addresses delayed mediator release from immune cells (mast cells, basophils, eosinophils, monocytes) triggered by reactive foods, causing systemic inflammation and chronic symptoms.
Question 2: Which inflammatory marker is most commonly associated with the systemic inflammation that LEAP therapy aims to reduce?
- Interleukin-4 (IL-4)
- C-reactive protein (CRP) (Correct answer)
- Immunoglobulin E (IgE)
- Histamine
Correct answer: C-reactive protein (CRP)
C-reactive protein (CRP) is a key systemic inflammatory marker often elevated in patients with food-triggered chronic inflammation that LEAP therapy targets.
Question 3: Leaky gut syndrome, often relevant to CLT clients, refers to which pathological condition?
- Excessive gastric acid production
- Increased intestinal permeability allowing antigens to enter the bloodstream (Correct answer)
- Insufficient digestive enzyme secretion
- Bacterial overgrowth in the small intestine only
Correct answer: Increased intestinal permeability allowing antigens to enter the bloodstream
Leaky gut (intestinal hyperpermeability) involves breakdown of tight junctions, allowing food antigens and toxins to enter the bloodstream and trigger immune responses.
Question 4: Which chronic condition is LEAST likely to have a food-sensitivity-driven inflammatory component addressed by LEAP therapy?
- Irritable bowel syndrome (IBS)
- Fibromyalgia
- Type 1 diabetes (acute phase) (Correct answer)
- Migraine headaches
Correct answer: Type 1 diabetes (acute phase)
Type 1 diabetes in its acute phase is an autoimmune condition requiring insulin therapy, and while diet matters, acute-phase management is outside the primary scope of LEAP food sensitivity therapy.
Question 5: How does chronic low-grade inflammation from food sensitivities differ from acute inflammation?
- It is always visible as redness and swelling
- It is self-limiting and resolves within 72 hours
- It persists over time without obvious localized signs, contributing to systemic symptoms (Correct answer)
- It only affects the gastrointestinal tract
Correct answer: It persists over time without obvious localized signs, contributing to systemic symptoms
Chronic low-grade inflammation from food sensitivities persists subclinically without obvious localized signs but drives systemic symptoms like fatigue, pain, and cognitive fog.
Question 6: Which dietary pattern is generally recommended as anti-inflammatory for CLT clients while their personalized MRT-based plan is being implemented?
- High-protein carnivore diet
- Elimination of all grains permanently
- Whole-food, minimally processed diet rich in colorful vegetables and omega-3 sources (Correct answer)
- Liquid-only diet for gut healing
Correct answer: Whole-food, minimally processed diet rich in colorful vegetables and omega-3 sources
A whole-food diet rich in colorful vegetables and omega-3 fatty acids provides anti-inflammatory phytonutrients and supports gut health during LEAP protocol implementation.
CLT CLT Inflammation & Chronic Disease Connections 1
In the context of LEAP therapy, what is the primary mechanism by which food-induced inflammation contributes to chronic symptoms?